Should Children With Bell's Palsy Be Treated With Corticosteroids? A Systematic Review

Salman, Mohammed Suliman Tawer; MacGregor,

doi:10.2310/7010.2001.16848

Cited by 9 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…54,66 The GDG identified 2 systematic reviews/meta-analyses that specifically addressed oral corticosteroid use in children. 67,68 Pitaro and Daniel 67 performed a systematic review of children diagnosed with new-onset Bell's palsy treated with steroids and found no controlled trials on the subject. Studies identified for inclusion in the systematic review had low evidence levels and concluded that the evidence for the use of steroids in children is inconclusive.…”

Section: Use Of Steroids In Children With Bell's Palsymentioning

confidence: 99%

Clinical Practice Guideline: Bell's Palsy

Baugh

Basura

Ishii

et al. 2013

Otolaryngol.--head neck surg.

389

114

View full text Add to dashboard Cite

Objective Bell’s palsy, named after the Scottish anatomist, Sir Charles Bell, is the most common acute mono-neuropathy, or disorder affecting a single nerve, and is the most common diagnosis associated with facial nerve weakness/paralysis. Bell’s palsy is a rapid unilateral facial nerve paresis (weakness) or paralysis (complete loss of movement) of unknown cause. The condition leads to the partial or complete inability to voluntarily move facial muscles on the affected side of the face. Although typically self-limited, the facial paresis/paralysis that occurs in Bell’s palsy may cause significant temporary oral incompetence and an inability to close the eyelid, leading to potential eye injury. Additional long-term poor outcomes do occur and can be devastating to the patient. Treatments are generally designed to improve facial function and facilitate recovery. There are myriad treatment options for Bell’s palsy, and some controversy exists regarding the effectiveness of several of these options, and there are consequent variations in care. In addition, numerous diagnostic tests available are used in the evaluation of patients with Bell’s palsy. Many of these tests are of questionable benefit in Bell’s palsy. Furthermore, while patients with Bell’s palsy enter the health care system with facial paresis/paralysis as a primary complaint, not all patients with facial paresis/paralysis have Bell’s palsy. It is a concern that patients with alternative underlying etiologies may be misdiagnosed or have unnecessary delay in diagnosis. All of these quality concerns provide an important opportunity for improvement in the diagnosis and management of patients with Bell’s palsy. Purpose The primary purpose of this guideline is to improve the accuracy of diagnosis for Bell’s palsy, to improve the quality of care and outcomes for patients with Bell’s palsy, and to decrease harmful variations in the evaluation and management of Bell’s palsy. This guideline addresses these needs by encouraging accurate and efficient diagnosis and treatment and, when applicable, facilitating patient follow-up to address the management of long-term sequelae or evaluation of new or worsening symptoms not indicative of Bell’s palsy. The guideline is intended for all clinicians in any setting who are likely to diagnose and manage patients with Bell’s palsy. The target population is inclusive of both adults and children presenting with Bell’s palsy. Action Statements The development group made a strong recommendation that (a) clinicians should assess the patient using history and physical examination to exclude identifiable causes of facial paresis or paralysis in patients presenting with acute-onset unilateral facial paresis or paralysis, (b) clinicians should prescribe oral steroids within 72 hours of symptom onset for Bell’s palsy patients 16 years and older, (c) clinicians should not prescribe oral antiviral therapy alone for patients with new-onset Bell’s palsy, and (d) clinicians should implement eye protection for Bell’s palsy patients with impaired eye closure. The panel made recommendations that (a) clinicians should not obtain routine laboratory testing in patients with new-onset Bell’s palsy, (b) clinicians should not routinely perform diagnostic imaging for patients with new-onset Bell’s palsy, (c) clinicians should not perform electrodiagnostic testing in Bell’s palsy patients with incomplete facial paralysis, and (d) clinicians should reassess or refer to a facial nerve specialist those Bell’s palsy patients with (1) new or worsening neurologic findings at any point, (2) ocular symptoms developing at any point, or (3) incomplete facial recovery 3 months after initial symptom onset. The development group provided the following options: (a) clinicians may offer oral antiviral therapy in addition to oral steroids within 72 hours of symptom onset for patients with Bell’s palsy, and (b) clinicians may offer electrodiagnostic testing to Bell’s palsy patients with complete facial paralysis. The development group offered the following no recommendations: (a) no recommendation can be made regarding surgical decompression for patients with Bell’s palsy, (b) no recommendation can be made regarding the effect of acupuncture in patients with Bell’s palsy, and (c) no recommendation can be made regarding the effect of physical therapy in patients with Bell’s palsy.

show abstract

Section: Use Of Steroids In Children With Bell's Palsymentioning

confidence: 99%

Clinical Practice Guideline: Bell's Palsy

Baugh

Basura

Ishii

et al. 2013

Otolaryngol.--head neck surg.

389

114

View full text Add to dashboard Cite

show abstract

“…Bei Kindern mit idiopathischer Fazialisparese gibt es bislang keine kontrollierten Studien, die belegen, dass auch bei ihnen eine Glukokortikoidtherapie hilfreich ist [55].…”

Section: Medikamentöse Therapieunclassified

Therapie der idiopathischen Fazialisparese (Bell’s palsy)

Heckmann

Läng²,

Glocker³

et al. 2017

Akt Neurol

View full text Add to dashboard Cite

ZusammenfassungDie periphere Fazialisparese ist die häufigste Hirnnervenläsion und wird klinisch diagnostiziert. Neurophysiologische Zusatzuntersuchungen können ergänzend zur Differenzierung und Prognoseabschätzung herangezogen werden. Der Anteil idiopathischer Fazialisparesen beträgt 60 – 75 %. Die übrigen 25 – 40 % lassen sich mit einer definierten Ätiologie in Zusammenhang bringen. Am häufigsten sind dabei die Neuroborreliose und der Zoster oticus (Ramsay-Hunt-Syndrom), seltener andere Infektionen. Weitere mögliche Auslöser sind die Sarkoidose (Heerfordt-Syndrom), das Sjögren-Syndrom, eine Meningeosis carcinomatosa, das Melkersson-Rosenthal-Syndrom, das Guillain-Barré-Syndrom, raumfordernde Prozesse im Kleinhirnbrückenwinkel, Frakturen des Felsenbeins, Parotistumoren und otogene Prozesse.Patienten mit idiopathischer Fazialisparese sollen mit Glukokortikoiden behandelt werden. Steroide begünstigen die vollständige Rückbildung und verringern das Risiko von Synkinesien, autonomen Störungen sowie Kontrakturen (Number needed to treat [NNT] 10; 95 % KI 6 – 20). Eine zusätzliche virustatische Therapie kann bei nur dezentem zusätzlichen Nutzen (< 7 %) nicht generell empfohlen werden. Patienten mit Fazialisparesen durch eine definierte Ätiologie werden ursachenbezogen behandelt. In der klinischen Praxis bewährt hat sich die symptomatische Therapie (Dexpanthenol-Augensalbe, Uhrglasverband) zum Schutz der Hornhaut. Eine zusätzliche Übungsbehandlung ist aus psychologischen Gründen angeraten. Nach Defektheilung können Methoden der Lidbeschwerung oder eine Tarsorrhaphie zur Erzielung eines hinreichenden Lidschlusses durchgeführt werden. In Einzelfällen sind operative mikrochirurgische Behandlungsmöglichkeiten zur Reanimation des N. fazialis in Betracht zu ziehen. Bei Schwangeren gelten grundsätzlich die gleichen diagnostischen und therapeutischen Prinzipien.

show abstract

“…One systematic review does not support the use of steroids in children. 49 Overall, the controversy that remains highlights the need for more randomized, controlled trials with greater number of patients to determine whether there is a real benefit from steroid therapy. 50 Antiviral Therapy Some evidence supports the use of antiviral agents in addition to steroid therapy and demonstrates improvement when compared with no treatment at all.…”

Section: Management Of Facial Paralysismentioning

confidence: 99%

Overview of Facial Paralysis: Current Concepts

Melvin

Limb

2008

Facial plast Surg

View full text Add to dashboard Cite

Facial paralysis represents the end result of a wide array of disorders and heterogeneous etiologies, including congenital, traumatic, infectious, neoplastic, and metabolic causes. Thus, facial palsy has a diverse range of presentations, from transient unilateral paresis to devastating permanent bilateral paralysis. Although not life-threatening, facial paralysis remains relatively common and can have truly severe effects on one's quality of life, with important ramifications in terms of psychological impact and physiologic burden. Prognosis and outcomes for patients with facial paralysis are highly dependent on the etiologic nature of the weakness as well as the treatment offered to the patient. Facial plastic surgeons are often asked to manage the sequelae of long-standing facial paralysis. It is important, however, for any practitioner who assists this population to have a sophisticated understanding of the common etiologies and initial management of facial paralysis. This article reviews the more common causes of facial paralysis and discusses relevant early treatment strategies.

show abstract

Should Children With Bell's Palsy Be Treated With Corticosteroids? A Systematic Review

Cited by 9 publications

References 0 publications

Clinical Practice Guideline: Bell's Palsy

Clinical Practice Guideline: Bell's Palsy

Therapie der idiopathischen Fazialisparese (Bell’s palsy)

Overview of Facial Paralysis: Current Concepts

Contact Info

Product

Resources

About